Clinical Report: Relationship Between the Triglyceride-Glucose Index and GBS

Overview

This study identifies the triglyceride-glucose (TyG) index as an independent risk factor for severe Guillain-Barré syndrome (GBS) and poor short-term prognosis. The TyG index, when combined with conventional clinical markers, enhances predictive accuracy for severe cases and adverse outcomes.

Background

Guillain-Barré syndrome (GBS) is an acute, immune-mediated disorder that can lead to significant morbidity and mortality. Early identification of patients at risk for severe progression or poor prognosis is essential for optimizing clinical management. The triglyceride-glucose (TyG) index, a marker of insulin resistance, may provide valuable prognostic information in GBS.

Data Highlights

Key Findings

• The TyG index is an independent risk factor for severe GBS (OR: 2.77).
• Higher albumin levels are protective against severe GBS (OR: 0.89).
• The MRC sum score is a protective factor for both severe GBS and poor short-term prognosis.
• The TyG index correlates with short-term poor prognosis (OR: 1.85).
• Combining the TyG index with clinical markers improves predictive accuracy for severe GBS (AUC: 0.808).

Clinical Implications

The TyG index may serve as a useful biomarker for identifying GBS patients at risk for severe outcomes. Incorporating the TyG index into clinical assessments could enhance early risk stratification and guide therapeutic interventions.

Conclusion

Elevated TyG index levels are associated with increased risks of severe GBS and poor short-term prognosis. This finding underscores the potential of the TyG index as a prognostic tool in clinical practice.

Related Resources & Content

1. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome - Doorn - 2023 - European Journal of Neurology - Wiley Online Library
2. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial - PubMed
3. Intravenous immunoglobulin for Guillain-Barré syndrome | Cochrane
4. Corticosteroids for Guillain-Barré syndrome | Cochrane
5. Frontiers in Neurology — Association between triglyceride glucose-body mass index and outcomes in patients with acute ischemic stroke: a retrospective secondary analysis of a prospective Korean cohort
6. Frontiers in Endocrinology — Association of TyG index with sepsis incidence and mortality: a prospective study with diabetes stratification
7. Frontiers in Cardiovascular Medicine — Independent prognostic value of the triglyceride–glucose index and its incremental predictive contribution beyond traditional risk markers in acute heart failure: a retrospective cohort study
8. Frontiers in Endocrinology — Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study
9. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome - Doorn - 2023 - European Journal of Neurology - Wiley Online Library
10. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial - PubMed
11. Intravenous immunoglobulin for Guillain-Barré syndrome | Cochrane
12. Corticosteroids for Guillain-Barré syndrome | Cochrane
13. International Validation of the Erasmus Guillain–Barré Syndrome Respiratory Insufficiency Score - PMC
14. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score - PMC
15. Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barré Syndrome | Neurology and Therapy | Springer Nature Link
16. Diagnostic Accuracy of the Triglyceride and Glucose Index for Insulin Resistance: A Systematic Review - PMC
17. Can the triglyceride-glucose index predict stroke outcomes? A systematic review and meta-analysis - PMC
18. Fasting Glucose Levels Correlate with Disease Severity of Guillain-Barré Syndrome - PMC